Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
31.46
+0.17 (0.54%)
Apr 3, 2025, 2:45 PM CST
SHA:600329 Revenue
In the year 2024, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 7.31B CNY, down -11.14%. Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.70B in the quarter ending December 31, 2024, a decrease of -30.19%.
Revenue
7.31B
Revenue Growth
-11.14%
P/S Ratio
3.29
Revenue / Employee
1.58M
Employees
4,619
Market Cap
21.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.31B | -915.58M | -11.14% |
Dec 31, 2023 | 8.22B | -26.94M | -0.33% |
Dec 31, 2022 | 8.25B | 1.34B | 19.42% |
Dec 31, 2021 | 6.91B | 303.89M | 4.60% |
Dec 31, 2020 | 6.60B | -390.23M | -5.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 27.98B |
Shenzhen Mindray Bio-Medical Electronics | 37.11B |
WuXi AppTec | 37.92B |
Aier Eye Hospital Group | 20.62B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
Shanghai United Imaging Healthcare | 10.30B |
Yunnan Baiyao Group Co.,Ltd | 40.03B |
Sichuan Biokin Pharmaceutical | 5.82B |